<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77398">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02118545</url>
  </required_header>
  <id_info>
    <org_study_id>Vie-Sal-Ber</org_study_id>
    <nct_id>NCT02118545</nct_id>
  </id_info>
  <brief_title>Von Willebrand Factor to Predict Postoperative Outcome</brief_title>
  <official_title>Preoperative Von Willebrand Factor to Predict Postoperative Liver Dysfunction and Morbidity After Liver Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <authority>Austria: Medical University of Vienna</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      vWF is stored in weibel-palade-bodies of endothelial cells as well as alpha-granula of
      platelets and is released upon their activation. Endothelial cell dysfunction as well as
      platelet activation often occur in liver disease and portal hypertension, which may lead to
      an increase in circulating vWF levels. Indeed, multiple studies have reported that liver
      disease is associated with increased circulating vWF- antigen (vWF-Ag). Furthermore,
      increased circulating vWF -Ag Levels have been shown to be associated with increased
      mortality rates in patients with chronic liver disease.  Within a prospective evaluation
      cohort, the investigators were able to document that patients with increased vWF-Ag levels
      prior to liver resection suffered from an increased incidence of postoperative liver
      dysfunction and morbidity. Within this prospective multicenter validation study, the
      investigators now aim to prospectively validate that circulating vWF-Ag prior to liver
      resection is a valuable marker to predict postoperative clinical outcome.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of Participants with Postoperative Liver Dysfunction</measure>
    <time_frame>90 postoperative days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Preoperative vWF-Ag Predicts Postoperative Liver Dysfunction after Liver Resection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Postoperative Morbidity</measure>
    <time_frame>90 postoperative days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Preoperative vWF-Ag Predicts Postoperative Morbidity after Liver Resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Postoperative Mortality</measure>
    <time_frame>90 postoperative days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Preoperative vWF-Ag Predicts Postoperative Mortality after Liver Resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of Postoperative Hospitalisation</measure>
    <time_frame>90 postoperative days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Preoperative vWF-Ag Predicts Postoperative Hospitalisation after Liver Resection</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Liver Dysfunction</condition>
  <condition>Morbidity</condition>
  <condition>Mortality</condition>
  <condition>Hospitalisation</condition>
  <arm_group>
    <arm_group_label>vWF and postoperative Outcome</arm_group_label>
    <description>Three independent prospective validation cohorts will be obtained in Vienna (N=40), Salzburg (N=40) and Bern (N=40)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing liver resections for either hepatocellular carcinoma,
        cholangiocellular carcinoma or colorectal cancer liver metastasis. vWF-Ag will be
        evaluated prior to liver resection
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing liver resection

          -  only patients with either hepatocellular carcinoma, cholangiocellular carcinoma or
             colorectal cancer liver metastasis will be included

        Exclusion Criteria:

          -  inherited coagulopathy

          -  age &gt; 85
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Starlinger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Gruenberger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rudolf Foundation Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Stättner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Paracelsus Medical University Salzburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guido Beldi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Bern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Starlinger, MD, PhD</last_name>
    <phone>0043 40400 5621</phone>
    <email>patrick.starlinger@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Gruenberger, MD</last_name>
    <phone>0043 40400 5621</phone>
    <email>thomas.gruenberger@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Paracelsus Medical University</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Stättner, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stefan Stättner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rudolf Foundation Clinic</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Gruenberger, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Gruenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Starlinger</last_name>
      <phone>00431404005621</phone>
      <email>patrick.starlinger@meduniwienac.at</email>
    </contact>
    <investigator>
      <last_name>Patrick Starlinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guido Beldi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guido Beldi, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>April 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Patrick Starlinger</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>vWF</keyword>
  <keyword>Liver Resection</keyword>
  <keyword>Liver Dysfunction</keyword>
  <keyword>Liver Regeneration</keyword>
  <keyword>Postoperative Outcome</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
